BioCatalyst

ALK-001 — catalyst calendar

1 verified catalyst event(s) referencing ALK-001, each linked to its official source. Verified as of 2026-09-20.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12 (month)
in 2mo
ESTIMATED
 READOUT
Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (
Phase 2 · Stargardt Disease, Stargardt Macular Degeneration
 Alkeus Pharmaceuticals, Inc. ALK-001 ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.